You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAmlodipine
Accession NumberDB00381  (APRD00520)
TypeSmall Molecule
GroupsApproved
DescriptionAmlodipine is a long-acting 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, amlodipine prevents calcium-dependent myocyte contraction and vasoconstriction. A second proposed mechanism for the drug’s vasodilatory effects involves pH-dependent inhibition of calcium influx via inhibition of smooth muscle carbonic anhydrase. Some studies have shown that amlodipine also exerts inhibitory effects on voltage-gated N-type calcium channels. N-type calcium channels located in the central nervous system may be involved in nociceptive signaling and pain sensation. Amlodipine is used to treat hypertension and chronic stable angina.
Structure
Thumb
Synonyms
(RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
3-Ethyl 5-methylester, (±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
Amlodipine
Amlodipine free base
Amlodipino
Amlodipinum
External Identifiers
  • UK 48340-11
  • UK 48340-26
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-amlodipineTablet10 mgOralAccel Pharma Inc2010-03-052016-10-19Canada
Accel-amlodipineTablet2.5 mgOralAccel Pharma IncNot applicableNot applicableCanada
Accel-amlodipineTablet5 mgOralAccel Pharma Inc2010-03-052016-10-19Canada
Act AmlodipineTablet2.5 mgOralActavis Pharma Company2010-03-02Not applicableCanada
Act AmlodipineTablet5 mgOralActavis Pharma Company2009-07-10Not applicableCanada
Act AmlodipineTablet10 mgOralActavis Pharma Company2009-07-10Not applicableCanada
Ag-amlodipineTablet5 mgOralAngita Pharma Inc.2014-09-25Not applicableCanada
Ag-amlodipineTablet10 mgOralAngita Pharma Inc.2014-09-25Not applicableCanada
Ag-amlodipineTablet2.5 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
AmlodipineTablet2.5 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
AmlodipineTablet5 mgOralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
AmlodipineTablet2.5 mgOralMeliapharm Inc2011-04-082014-06-25Canada
AmlodipineTablet5 mgOralSanis Health Inc2009-10-22Not applicableCanada
AmlodipineTablet2.5 mgOralPro Doc Limitee2009-07-22Not applicableCanada
AmlodipineTablet5 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
AmlodipineTablet10 mgOralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
AmlodipineTablet5 mgOralMeliapharm Inc2011-04-082014-06-25Canada
AmlodipineTablet10 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
AmlodipineTablet10 mgOralSanis Health Inc2009-10-22Not applicableCanada
AmlodipineTablet5.0 mgOralPro Doc Limitee2009-07-22Not applicableCanada
AmlodipineTablet10 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
AmlodipineTablet10 mgOralMeliapharm Inc2011-04-082014-06-25Canada
AmlodipineTablet5 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
AmlodipineTablet5 mgOralJamp Pharma Corporation2014-09-04Not applicableCanada
AmlodipineTablet10 mgOralJamp Pharma Corporation2014-09-04Not applicableCanada
AmlodipineTablet2.5 mgOralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
AmlodipineTablet10.0 mgOralPro Doc Limitee2009-07-22Not applicableCanada
Amlodipine BesylateTablet10 mg/1OralRed Pharm Drug Inc.1992-07-31Not applicableUs
Amlodipine BesylateTablet10 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1992-07-31Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralPd Rx Pharmaceuticals, Inc.1992-07-31Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralSt Marys Medical Park Pharmacy2014-05-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralKAISER FOUNDATION HOSPITALS2008-10-21Not applicableUs
Amlodipine BesylateTablet10 mg/1OralAvera Mc Kennan Hospital2015-07-21Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralGreenstone LLC2007-03-23Not applicableUs
Amlodipine BesylateTablet10 mg/1OralContract Pharmacy Services Pa1992-07-31Not applicableUs
Amlodipine BesylateTablet5 mg/1OralKAISER FOUNDATION HOSPITALS2008-10-21Not applicableUs
Amlodipine BesylateTablet5 mg/1OralGreenstone LLC2007-03-23Not applicableUs
Amlodipine BesylateTablet5 mg/1OralRed Pharm Drug Inc.1992-07-31Not applicableUs
Amlodipine BesylateTablet5 mg/1OralCardinal Health1992-07-31Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralKAISER FOUNDATION HOSPITALS2008-10-21Not applicableUs
Amlodipine BesylateTablet10 mg/1OralGreenstone LLC2007-03-23Not applicableUs
Amlodipine BesylateTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.1992-07-31Not applicableUs
Amlodipine Besylate Tablets USPTablet2.5 mgOralAccord Healthcare IncNot applicableNot applicableCanada
Amlodipine Besylate Tablets USPTablet5 mgOralAccord Healthcare IncNot applicableNot applicableCanada
Amlodipine Besylate Tablets USPTablet10 mgOralAccord Healthcare IncNot applicableNot applicableCanada
Amlodipine Besylate Tablets, 10mgTablet10.0 mgOralDr Reddys Laboratories IncNot applicableNot applicableCanada
Amlodipine Besylate Tablets, 5mgTablet5.0 mgOralDr Reddys Laboratories IncNot applicableNot applicableCanada
Amlodipine TabletsTablet10 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Amlodipine TabletsTablet5 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Amlodipine-odanTablet5.0 mgOralOdan Laboratories Ltd2012-03-082014-11-12Canada
Amlodipine-odanTablet10.0 mgOralOdan Laboratories Ltd2012-03-082014-11-12Canada
Amlodipine-odanTablet2.5 mgOralOdan Laboratories Ltd2012-03-082012-12-31Canada
Auro-amlodipineTablet10 mgOralAuro Pharma Inc2013-02-12Not applicableCanada
Auro-amlodipineTablet5 mgOralAuro Pharma Inc2013-02-12Not applicableCanada
Bio-amlodipineTablet5.00 mgOralBiomed Pharma2013-01-15Not applicableCanada
Bio-amlodipineTablet10.00 mgOralBiomed Pharma2013-01-15Not applicableCanada
Bio-amlodipineTablet2.5 mgOralBiomed Pharma2013-01-15Not applicableCanada
Dom-amlodipineTablet2.5 mgOralDominion Pharmacal2010-01-13Not applicableCanada
Dom-amlodipineTablet5.0 mgOralDominion Pharmacal2010-01-13Not applicableCanada
Dom-amlodipineTablet10.0 mgOralDominion Pharmacal2010-01-13Not applicableCanada
Gd-amlodipineTablet10 mgOralGenmed A Division Of Pfizer Canada Inc2009-07-22Not applicableCanada
Gd-amlodipineTablet2.5 mgOralGenmed A Division Of Pfizer Canada Inc2012-07-23Not applicableCanada
Gd-amlodipineTablet5 mgOralGenmed A Division Of Pfizer Canada Inc2009-07-22Not applicableCanada
Ipg-amlodipineTablet10 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-amlodipineTablet2.5 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-amlodipineTablet5 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-amlodipineTablet2.5 mgOralJamp Pharma Corporation2011-01-27Not applicableCanada
Jamp-amlodipineTablet5 mgOralJamp Pharma Corporation2011-01-27Not applicableCanada
Jamp-amlodipineTablet10 mgOralJamp Pharma Corporation2011-01-27Not applicableCanada
Jamp-amlodipineTablet5 mgOralJamp Pharma Corporation2010-03-182014-11-07Canada
Jamp-amlodipineTablet10 mgOralJamp Pharma Corporation2010-03-182014-11-07Canada
Manda-amlodipine TabletsTablet2.5 mgOralManda Pharma Inc2012-06-012013-08-22Canada
Manda-amlodipine TabletsTablet5 mgOralManda Pharma Inc2012-06-012013-08-22Canada
Manda-amlodipine TabletsTablet10 mgOralManda Pharma Inc2012-06-012013-08-22Canada
Mar-amlodipine TabletsTablet2.5 mgOralMarcan Pharmaceuticals Inc2012-10-24Not applicableCanada
Mar-amlodipine TabletsTablet5 mgOralMarcan Pharmaceuticals Inc2012-10-24Not applicableCanada
Mar-amlodipine TabletsTablet10 mgOralMarcan Pharmaceuticals Inc2012-10-24Not applicableCanada
Mint-amlodipineTablet5 mgOralMint Pharmaceuticals Inc2011-02-16Not applicableCanada
Mint-amlodipineTablet10 mgOralMint Pharmaceuticals Inc2011-02-16Not applicableCanada
Mylan-amlodipineTablet5.0 mgOralMylan Pharmaceuticals Ulc2009-07-09Not applicableCanada
Mylan-amlodipineTablet10.0 mgOralMylan Pharmaceuticals Ulc2009-07-09Not applicableCanada
NorvascTablet2.5 mg/1OralPfizer Laboratories Div Pfizer Inc1992-07-31Not applicableUs
NorvascTablet5 mg/1OralCardinal Health1992-07-31Not applicableUs
NorvascTablet10 mg/1OralLake Erie Medical & Surgical Supplies DBA Quality Care Products LLC2011-11-22Not applicableUs
NorvascTablet5 mg/1OralPfizer Laboratories Div Pfizer Inc1992-07-31Not applicableUs
NorvascTablet10 mg/1OralCardinal Health1992-07-31Not applicableUs
NorvascTablet10 mg/1OralREMEDYREPACK INC.2013-03-042016-04-05Us
NorvascTablet10 mg/1OralPfizer Laboratories Div Pfizer Inc1992-07-31Not applicableUs
NorvascTablet5 mg/1OralPd Rx Pharmaceuticals, Inc.1992-07-31Not applicableUs
NorvascTablet5 mg/1OralRebel Distributors Corp1992-07-31Not applicableUs
Norvasc Tab 10mgTablet10 mgOralPfizer Canada Inc1992-12-31Not applicableCanada
Norvasc Tab 2.5mgTablet2.5 mgOralPfizer Canada IncNot applicableNot applicableCanada
Norvasc Tab 5mgTablet5 mgOralPfizer Canada Inc1992-12-31Not applicableCanada
PHL-amlodipineTablet10.0 mgOralPharmel Inc2009-07-16Not applicableCanada
PHL-amlodipineTablet2.5 mgOralPharmel Inc2009-07-21Not applicableCanada
PHL-amlodipineTablet5.0 mgOralPharmel Inc2009-07-16Not applicableCanada
PMS-amlodipineTablet5.0 mgOralPharmascience Inc2009-07-09Not applicableCanada
PMS-amlodipineTablet10.0 mgOralPharmascience Inc2009-07-09Not applicableCanada
PMS-amlodipineTablet2.5 mgOralPharmascience Inc2009-07-15Not applicableCanada
Priva-amlodipineTablet5 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-amlodipineTablet10 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-amlodipineTablet2.5 mgOralPharmapar IncNot applicableNot applicableCanada
Q-amlodipineTablet5 mgOralQd Pharmaceuticals Ulc2011-10-032015-08-21Canada
Q-amlodipineTablet10 mgOralQd Pharmaceuticals Ulc2011-10-032015-08-21Canada
Q-gen AmlodipineTablet5 mgOralQ Gen Pharmaceuticals IncNot applicableNot applicableCanada
Q-gen AmlodipineTablet10 mgOralQ Gen Pharmaceuticals IncNot applicableNot applicableCanada
Ran-amlodipineTablet5 mgOralRanbaxy Pharmaceuticals Canada Inc.2009-07-09Not applicableCanada
Ran-amlodipineTablet10 mgOralRanbaxy Pharmaceuticals Canada Inc.2009-07-09Not applicableCanada
Ran-amlodipineTablet2.5 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-06-07Not applicableCanada
Ratio-amlodipine Tablets 10mgTablet10 mgOralRatiopharm Inc Division Of Teva Canada Limited2009-07-092014-09-19Canada
Ratio-amlodipine Tablets 5mgTablet5 mgOralRatiopharm Inc Division Of Teva Canada Limited2009-07-092014-09-19Canada
Riva-amlodipineTablet2.5 mgOralLaboratoire Riva Inc2009-10-13Not applicableCanada
Riva-amlodipineTablet5 mgOralLaboratoire Riva Inc2009-10-07Not applicableCanada
Riva-amlodipineTablet10 mgOralLaboratoire Riva Inc2009-10-06Not applicableCanada
Sandoz AmlodipineTablet10 mgOralSandoz Canada Incorporated2009-07-09Not applicableCanada
Sandoz AmlodipineTablet5 mgOralSandoz Canada Incorporated2009-07-09Not applicableCanada
Sandoz AmlodipineTablet5 mgOralSandoz Canada Incorporated2009-07-09Not applicableCanada
Sandoz AmlodipineTablet10 mgOralSandoz Canada Incorporated2009-07-09Not applicableCanada
Sandoz AmlodipineTablet2.5 mgOralSandoz Canada Incorporated2009-08-05Not applicableCanada
Septa-amlodipineTablet5 mgOralSepta Pharmaceuticals Inc2010-11-22Not applicableCanada
Septa-amlodipineTablet10 mgOralSepta Pharmaceuticals Inc2010-11-22Not applicableCanada
Septa-amlodipineTablet2.5 mgOralSepta Pharmaceuticals Inc2010-11-22Not applicableCanada
Teva-amlodipineTablet5 mgOralTeva Canada Limited2009-07-09Not applicableCanada
Teva-amlodipineTablet10 mgOralTeva Canada Limited2009-07-09Not applicableCanada
Van-amlodipineTablet5 mgOralVanc Pharmaceuticals Inc2015-06-22Not applicableCanada
Van-amlodipineTablet10 mgOralVanc Pharmaceuticals Inc2015-06-22Not applicableCanada
Zym-amlodipineTablet5.0 mgOralZymcan Pharmaceuticals Inc2010-04-292014-06-16Canada
Zym-amlodipineTablet10.0 mgOralZymcan Pharmaceuticals Inc2010-04-292014-06-16Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmlodipineTablet10 mg/1OralREMEDYREPACK INC.2011-04-132016-10-13Us
AmlodipineTablet10 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
AmlodipineTablet5 mg/1OralMacleods Pharmaceuticals Limited2012-04-13Not applicableUs
AmlodipineTablet10 mg/1OralMacleods Pharmaceuticals Limited2012-04-13Not applicableUs
Amlodipine BesylateTablet5 mg/1OralLegacy Pharmaceutical Packaging, Llc2011-01-01Not applicableUs
Amlodipine BesylateTablet5 mg/1OralMylan Institutional Inc.2007-04-02Not applicableUs
Amlodipine BesylateTablet5 mg/1OralDIRECT RX2014-01-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralZydus Pharmaceuticals (USA) Inc.2007-09-21Not applicableUs
Amlodipine BesylateTablet5 mg/1OralA S Medication Solutions2014-03-03Not applicableUs
Amlodipine BesylateTablet5 mg/1OralCipla USA Inc.2016-07-01Not applicableUs
Amlodipine BesylateTablet5 mg/1OralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2012-10-19Not applicableUs
Amlodipine BesylateTablet10 mg/1OralProficient Rx LP2011-01-01Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralREMEDYREPACK INC.2013-12-31Not applicableUs
Amlodipine BesylateTablet10 mg/1OralAmneal Pharmaceuticals of New York, LLC2010-06-21Not applicableUs
Amlodipine BesylateTablet5 mg/1OralCardinal Health2007-09-062016-11-30Us
Amlodipine BesylateTablet5 mg/1OralCipla USA Inc.2007-09-26Not applicableUs
Amlodipine BesylateTablet5 mg/1OralMajor Pharmaceuticals2013-01-20Not applicableUs
Amlodipine BesylateTablet5 mg/1OralMylan Pharmaceuticals Inc.2007-03-23Not applicableUs
Amlodipine BesylateTablet10 mg/1OralExelan Pharmaceuticals, Inc.2007-11-02Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralTeva Pharmaceuticals USA Inc2007-07-10Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralUnit Dose Services2011-01-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralWest Ward Pharmaceuticals Corp.2007-07-09Not applicableUs
Amlodipine BesylateTablet5 mg/1OralPolygen Pharmaceuticals Inc.2016-07-11Not applicableUs
Amlodipine BesylateTablet10 mg/1OralREMEDYREPACK INC.2015-02-26Not applicableUs
Amlodipine BesylateTablet10 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-11-02Not applicableUs
Amlodipine BesylateTablet10 mg/1OralClinical Solutions Wholesale, Llc2016-07-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralTorrent Pharmaceuticals Limited2009-02-05Not applicableUs
Amlodipine BesylateTablet5 mg/1OralPd Rx Pharmaceuticals, Inc.2010-06-21Not applicableUs
Amlodipine BesylateTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.2010-06-21Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralApotex Corp.2007-05-24Not applicableUs
Amlodipine BesylateTablet10 mg/1OralAv Pak2014-01-10Not applicableUs
Amlodipine BesylateTablet10 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2007-09-21Not applicableUs
Amlodipine BesylateTablet5 mg/1OralInternational Labs, Inc.2012-02-202016-10-13Us
Amlodipine BesylateTablet2.5 mg/1OralAmerican Health Packaging2014-02-03Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralUpsher Smith Laboratories, Inc.2007-07-09Not applicableUs
Amlodipine BesylateTablet5 mg/1OralMc Kesson Contract Packaging2011-09-14Not applicableUs
Amlodipine BesylateTablet5 mg/1OralBlenheim Pharmacal, Inc.2013-11-13Not applicableUs
Amlodipine BesylateTablet5 mg/1OralPreferred Pharmaceuticals, Inc.2010-04-07Not applicableUs
Amlodipine BesylateTablet10 mg/1OralQualitest Pharmaceuticals2010-04-07Not applicableUs
Amlodipine BesylateTablet5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-01-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralCardinal Health2013-01-20Not applicableUs
Amlodipine BesylateTablet5 mg/1OralAmerican Health Packaging2016-12-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-09-26Not applicableUs
Amlodipine BesylateTablet10 mg/1OralA S Medication Solutions2010-04-07Not applicableUs
Amlodipine BesylateTablet5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-11-04Not applicableUs
Amlodipine BesylateTablet10 mg/1OralHikma Pharmaceutical2011-04-12Not applicableUs
Amlodipine BesylateTablet5 mg/1OralREMEDYREPACK INC.2011-09-14Not applicableUs
Amlodipine BesylateTablet10 mg/1OralRanbaxy Pharmaceuticals Inc2007-07-09Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralAurobindo Pharma Limited2007-07-17Not applicableUs
Amlodipine BesylateTablet5 mg/1OralCardinal Health2014-02-03Not applicableUs
Amlodipine BesylateTablet5 mg/1OralTYA Pharmaceuticals2011-01-01Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralDr Reddy's Laboratories2007-07-23Not applicableUs
Amlodipine BesylateTablet10 mg/1OralPreferred Pharmaceuticals, Inc.2015-04-06Not applicableUs
Amlodipine BesylateTablet10 mg/1OralMajor Pharmaceuticals2010-12-03Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralAmerican Health Packaging2013-07-232015-12-29Us
Amlodipine BesylateTablet5 mg/1OralWest Ward Pharmaceuticals Corp2011-04-12Not applicableUs
Amlodipine BesylateTablet5 mg/1OralSt Marys Medical Park Pharmacy2013-04-25Not applicableUs
Amlodipine BesylateTablet5 mg/1OralChina Resources Saike Pharmaceutical Co., Ltd.2011-04-15Not applicableUs
Amlodipine BesylateTablet10 mg/1OralDIRECT RX2014-01-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralAscend Laboratories, LLC2010-10-20Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralA S Medication Solutions2014-03-03Not applicableUs
Amlodipine BesylateTablet10 mg/1OralLegacy Pharmaceutical Packaging, Llc2016-07-01Not applicableUs
Amlodipine BesylateTablet5 mg/1OralUnichem Pharmaceuticals (USA), Inc.2014-03-03Not applicableUs
Amlodipine BesylateTablet10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-04-07Not applicableUs
Amlodipine BesylateTablet5 mg/1OralMedsource Pharmaceuticals2014-03-03Not applicableUs
Amlodipine BesylateTablet5 mg/1OralDIRECT RX2015-01-01Not applicableUs
Amlodipine BesylateTablet5 mg/1OralREMEDYREPACK INC.2013-05-132016-04-05Us
Amlodipine BesylateTablet10 mg/1OralMylan Pharmaceuticals Inc.2007-03-23Not applicableUs
Amlodipine BesylateTablet5 mg/1OralAidarex Pharmaceuticals LLC2011-01-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralMylan Institutional Inc.2007-04-02Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralLupin Pharmaceuticals, Inc.2007-08-03Not applicableUs
Amlodipine BesylateTablet5 mg/1OralKAISER FOUNDATION HOSPITALS2016-07-08Not applicableUs
Amlodipine BesylateTablet10 mg/1OralA S Medication Solutions2014-03-03Not applicableUs
Amlodipine BesylateTablet10 mg/1OralCipla USA Inc.2016-07-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Amlodipine BesylateTablet5 mg/1OralREMEDYREPACK INC.2011-08-22Not applicableUs
Amlodipine BesylateTablet5 mg/1OralProficient Rx LP2014-03-03Not applicableUs
Amlodipine BesylateTablet10 mg/1OralREMEDYREPACK INC.2014-04-04Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralCadila Healthcare Limited2007-09-21Not applicableUs
Amlodipine BesylateTablet5 mg/1OralCardinal Health2011-06-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralCipla USA Inc.2007-09-26Not applicableUs
Amlodipine BesylateTablet10 mg/1OralMajor Pharmaceuticals2013-01-20Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralMajor Pharmaceuticals2009-06-102015-12-31Us
Amlodipine BesylateTablet5 mg/1OralTeva Pharmaceuticals USA Inc2007-07-10Not applicableUs
Amlodipine BesylateTablet10 mg/1OralProficient Rx LP2014-03-03Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralEpic Pharma, LLC2011-04-25Not applicableUs
Amlodipine BesylateTablet10 mg/1OralPolygen Pharmaceuticals Inc.2016-07-11Not applicableUs
Amlodipine BesylateTablet5 mg/1OralREMEDYREPACK INC.2015-02-26Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralChina Resources Saike Pharmaceutical Co., Ltd.2011-04-15Not applicableUs
Amlodipine BesylateTablet10 mg/1OralREMEDYREPACK INC.2016-07-06Not applicableUs
Amlodipine BesylateTablet5 mg/1OralSTAT Rx USA LLC2007-09-06Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralWockhardt Limited2007-09-06Not applicableUs
Amlodipine BesylateTablet5 mg/1OralPd Rx Pharmaceuticals, Inc.2010-10-20Not applicableUs
Amlodipine BesylateTablet5 mg/1OralApotex Corp.2007-05-24Not applicableUs
Amlodipine BesylateTablet5 mg/1OralUnit Dose Services2010-04-07Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralWockhardt USA LLC.2007-09-06Not applicableUs
Amlodipine BesylateTablet5 mg/1OralPhysicians Total Care, Inc.2007-03-28Not applicableUs
Amlodipine BesylateTablet5 mg/1OralAmerican Health Packaging2014-02-03Not applicableUs
Amlodipine BesylateTablet5 mg/1OralUpsher Smith Laboratories, Inc.2007-07-09Not applicableUs
Amlodipine BesylateTablet10 mg/1Oralbryant ranch prepack2007-05-24Not applicableUs
Amlodipine BesylateTablet5 mg/1OralAurobindo Pharma Limited2007-07-17Not applicableUs
Amlodipine BesylateTablet10 mg/1OralCardinal Health2010-01-14Not applicableUs
Amlodipine BesylateTablet10 mg/1OralMc Kesson Contract Packaging2011-09-14Not applicableUs
Amlodipine BesylateTablet10 mg/1OralBlenheim Pharmacal, Inc.2011-04-25Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralBiomes Pharmaceuticals LLC2011-04-15Not applicableUs
Amlodipine BesylateTablet5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-03-11Not applicableUs
Amlodipine BesylateTablet10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-01-01Not applicableUs
Amlodipine BesylateTablet5 mg/1OralCardinal Health2013-01-20Not applicableUs
Amlodipine BesylateTablet10 mg/1OralAmerican Health Packaging2016-12-01Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-09-26Not applicableUs
Amlodipine BesylateTablet10 mg/1OralClinical Solutions Wholesale, Llc2011-01-01Not applicableUs
Amlodipine BesylateTablet5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-04-07Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralGolden State Medical Supply, Inc.2011-04-25Not applicableUs
Amlodipine BesylateTablet5 mg/1OralREMEDYREPACK INC.2013-04-102016-10-15Us
Amlodipine BesylateTablet2.5 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2012-10-19Not applicableUs
Amlodipine BesylateTablet5 mg/1OralSafecor Health, LLC2014-09-30Not applicableUs
Amlodipine BesylateTablet10 mg/1OralProficient Rx LP2010-04-07Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralREMEDYREPACK INC.2013-06-14Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralAmneal Pharmaceuticals of New York, LLC2010-06-21Not applicableUs
Amlodipine BesylateTablet5 mg/1OralDr Reddy's Laboratories2007-07-23Not applicableUs
Amlodipine BesylateTablet5 mg/1OralPreferred Pharmaceuticals, Inc.2014-11-24Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralMajor Pharmaceuticals2010-12-03Not applicableUs
Amlodipine BesylateTablet5 mg/1OralAmerican Health Packaging2013-07-232015-12-29Us
Amlodipine BesylateTablet10 mg/1OralWest Ward Pharmaceuticals Corp2011-04-12Not applicableUs
Amlodipine BesylateTablet10 mg/1OralSt Marys Medical Park Pharmacy2011-09-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralChina Resources Saike Pharmaceutical Co., Ltd.2011-04-15Not applicableUs
Amlodipine BesylateTablet5 mg/1OralPreferred Pharmaceutical Inc.2016-11-07Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralZydus Pharmaceuticals (USA) Inc.2007-09-21Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralA S Medication Solutions2011-01-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralPreferred Pharmaceuticals Inc.2016-05-04Not applicableUs
Amlodipine BesylateTablet10 mg/1OralUnichem Pharmaceuticals (USA), Inc.2014-03-03Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralQualitest Pharmaceuticals2010-04-07Not applicableUs
Amlodipine BesylateTablet10 mg/1OralAidarex Pharmaceuticals LLC2011-01-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralREMEDYREPACK INC.2013-01-04Not applicableUs
Amlodipine BesylateTablet5 mg/1OralLupin Pharmaceuticals, Inc.2007-08-03Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralKAISER FOUNDATION HOSPITALS2016-07-08Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralA S Medication Solutions2010-10-20Not applicableUs
Amlodipine BesylateTablet5 mg/1OralUnit Dose Services2007-09-26Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralHikma Pharmaceutical2011-04-12Not applicableUs
Amlodipine BesylateTablet10 mg/1OralREMEDYREPACK INC.2011-08-22Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralRanbaxy Pharmaceuticals Inc2007-07-09Not applicableUs
Amlodipine BesylateTablet5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Amlodipine BesylateTablet5 mg/1OralCadila Healthcare Limited2007-09-21Not applicableUs
Amlodipine BesylateTablet10 mg/1OralCardinal Health2009-06-10Not applicableUs
Amlodipine BesylateTablet10 mg/1OralAvera Mc Kennan Hospital2015-03-05Not applicableUs
Amlodipine BesylateTablet10 mg/1OralBlenheim Pharmacal, Inc.2012-01-18Not applicableUs
Amlodipine BesylateTablet5 mg/1OralAv Pak2011-06-072015-12-29Us
Amlodipine BesylateTablet10 mg/1OralTeva Pharmaceuticals USA Inc2007-07-10Not applicableUs
Amlodipine BesylateTablet5 mg/1OralClinical Solutions Wholesale2011-01-012016-10-13Us
Amlodipine BesylateTablet5 mg/1OralEpic Pharma, LLC2011-04-25Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralPreferred Pharmaceuticals, Inc.2016-10-25Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralAscend Laboratories, LLC2010-10-20Not applicableUs
Amlodipine BesylateTablet5 mg/1OralA S Medication Solutions2010-04-07Not applicableUs
Amlodipine BesylateTablet10 mg/1OralREMEDYREPACK INC.2016-08-15Not applicableUs
Amlodipine BesylateTablet10 mg/1OralREMEDYREPACK INC.2013-02-272016-04-05Us
Amlodipine BesylateTablet5 mg/1OralWockhardt Limited2007-09-06Not applicableUs
Amlodipine BesylateTablet5 mg/1OralAphena Pharma Solutions Tennessee, Llc2010-04-07Not applicableUs
Amlodipine BesylateTablet10 mg/1OralApotex Corp.2007-05-24Not applicableUs
Amlodipine BesylateTablet10 mg/1OralNorthwind Pharmaceuticals, LLC2014-09-21Not applicableUs
Amlodipine BesylateTablet5 mg/1OralWockhardt USA LLC.2007-09-06Not applicableUs
Amlodipine BesylateTablet10 mg/1OralPhysicians Total Care, Inc.2007-03-28Not applicableUs
Amlodipine BesylateTablet10 mg/1OralAmerican Health Packaging2014-02-03Not applicableUs
Amlodipine BesylateTablet10 mg/1OralUpsher Smith Laboratories, Inc.2007-07-09Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-04-07Not applicableUs
Amlodipine BesylateTablet5 mg/1OralGolden State Medical Supply, Inc.2011-04-25Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralAv Pak2014-01-10Not applicableUs
Amlodipine BesylateTablet5 mg/1Oralbryant ranch prepack2007-05-24Not applicableUs
Amlodipine BesylateTablet5 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralAurobindo Pharma Limited2007-07-17Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralCardinal Health2010-01-14Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralExelan Pharmaceuticals, Inc.2007-11-02Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralTorrent Pharmaceuticals Limited2009-02-05Not applicableUs
Amlodipine BesylateTablet5 mg/1OralBiomes Pharmaceuticals LLC2011-04-15Not applicableUs
Amlodipine BesylateTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-03-11Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralWest Ward Pharmaceuticals Corp.2007-07-09Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralClinical Solutions Wholesale2010-04-07Not applicableUs
Amlodipine BesylateTablet5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-09-26Not applicableUs
Amlodipine BesylateTablet5 mg/1OralClinical Solutions Wholesale, Llc2011-01-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralA S Medication Solutions2011-01-01Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralCipla USA Inc.2016-07-01Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs
Amlodipine BesylateTablet5 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2012-10-19Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralREMEDYREPACK INC.2011-04-08Not applicableUs
Amlodipine BesylateTablet5 mg/1OralProficient Rx LP2011-01-01Not applicableUs
Amlodipine BesylateTablet5 mg/1OralREMEDYREPACK INC.2013-12-05Not applicableUs
Amlodipine BesylateTablet5 mg/1OralAmneal Pharmaceuticals of New York, LLC2010-06-21Not applicableUs
Amlodipine BesylateTablet10 mg/1OralDr Reddy's Laboratories2007-07-23Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralCipla USA Inc.2007-09-26Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralMajor Pharmaceuticals2013-01-20Not applicableUs
Amlodipine BesylateTablet10 mg/1OralAmerican Health Packaging2013-07-232015-12-29Us
Amlodipine BesylateTablet2.5 mg/1OralMylan Pharmaceuticals Inc.2007-03-23Not applicableUs
Amlodipine BesylateTablet5 mg/1OralREMEDYREPACK INC.2014-10-202016-04-05Us
Amlodipine BesylateTablet2.5 mg/1OralMylan Institutional Inc.2007-04-02Not applicableUs
Amlodipine BesylateTablet10 mg/1OralPreferred Pharmaceutical Inc.2016-11-07Not applicableUs
Amlodipine BesylateTablet5 mg/1OralZydus Pharmaceuticals (USA) Inc.2007-09-21Not applicableUs
Amlodipine BesylateTablet10 mg/1OralPreferred Pharmaceuticals, Inc.2010-04-07Not applicableUs
Amlodipine BesylateTablet5 mg/1OralQualitest Pharmaceuticals2010-04-07Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralAidarex Pharmaceuticals LLC2011-01-01Not applicableUs
Amlodipine BesylateTablet5 mg/1OralCardinal Health2014-01-10Not applicableUs
Amlodipine BesylateTablet10 mg/1OralLupin Pharmaceuticals, Inc.2007-08-03Not applicableUs
Amlodipine BesylateTablet10 mg/1OralKAISER FOUNDATION HOSPITALS2016-07-08Not applicableUs
Amlodipine BesylateTablet5 mg/1OralA S Medication Solutions2014-03-03Not applicableUs
Amlodipine BesylateTablet10 mg/1OralUnit Dose Services2007-09-26Not applicableUs
Amlodipine BesylateTablet5 mg/1OralHikma Pharmaceutical2011-04-12Not applicableUs
Amlodipine BesylateTablet10 mg/1OralREMEDYREPACK INC.2011-09-14Not applicableUs
Amlodipine BesylateTablet5 mg/1OralRanbaxy Pharmaceuticals Inc2007-07-09Not applicableUs
Amlodipine BesylateTablet10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralCadila Healthcare Limited2007-09-21Not applicableUs
Amlodipine BesylateTablet5 mg/1OralCardinal Health2011-06-07Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralMc Kesson Contract Packaging2011-09-14Not applicableUs
Amlodipine BesylateTablet5 mg/1OralBlenheim Pharmacal, Inc.2012-01-18Not applicableUs
Amlodipine BesylateTablet10 mg/1OralAv Pak2011-06-072015-12-29Us
Amlodipine BesylateTablet2.5 mg/1OralWest Ward Pharmaceuticals Corp2011-04-12Not applicableUs
Amlodipine BesylateTablet10 mg/1OralClinical Solutions Wholesale2011-01-012016-10-13Us
Amlodipine BesylateTablet10 mg/1OralEpic Pharma, LLC2011-04-25Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralUnit Dose Services2014-03-03Not applicableUs
Amlodipine BesylateTablet5 mg/1OralAscend Laboratories, LLC2010-10-20Not applicableUs
Amlodipine BesylateTablet10 mg/1OralA S Medication Solutions2010-04-07Not applicableUs
Amlodipine BesylateTablet5 mg/1OralLegacy Pharmaceutical Packaging, Llc2016-07-01Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralUnichem Pharmaceuticals (USA), Inc.2014-03-03Not applicableUs
Amlodipine BesylateTablet10 mg/1OralWockhardt Limited2007-09-06Not applicableUs
Amlodipine BesylateTablet10 mg/1OralAphena Pharma Solutions Tennessee, Llc2010-04-07Not applicableUs
Amlodipine BesylateTablet5 mg/1OralREMEDYREPACK INC.2015-06-19Not applicableUs
Amlodipine BesylateTablet5 mg/1OralNorthwind Pharmaceuticals, LLC2014-09-23Not applicableUs
Amlodipine BesylateTablet10 mg/1OralWockhardt USA LLC.2007-09-06Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralPhysicians Total Care, Inc.2007-04-06Not applicableUs
Amlodipine BesylateTablet10 mg/1OralCarilion Materials Management2011-01-01Not applicableUs
Amlodipine BesylateTablet5 mg/1OralMajor Pharmaceuticals2010-12-03Not applicableUs
Amlodipine BesylateTablet10 mg/1OralApotheca Inc.2011-01-01Not applicableUs
Amlodipine BesylateTablet5 mg/1OralClinical Solutions Wholesale, Llc2016-07-01Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralPolygen Pharmaceuticals Inc.2016-07-11Not applicableUs
Amlodipine BesylateTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.2010-10-20Not applicableUs
Amlodipine BesylateTablet10 mg/1OralGolden State Medical Supply, Inc.2011-04-25Not applicableUs
Amlodipine BesylateTablet5 mg/1OralAv Pak2014-01-10Not applicableUs
Amlodipine BesylateTablet2.5 mg/1Oralbryant ranch prepack2007-05-24Not applicableUs
Amlodipine BesylateTablet10 mg/1OralInternational Labs, Inc.2012-09-142016-10-13Us
Amlodipine BesylateTablet5 mg/1OralMed Vantx, Inc.2010-03-23Not applicableUs
Amlodipine BesylateTablet5 mg/1OralCardinal Health2010-01-14Not applicableUs
Amlodipine BesylateTablet5 mg/1OralExelan Pharmaceuticals, Inc.2007-11-02Not applicableUs
Amlodipine BesylateTablet5 mg/1OralTorrent Pharmaceuticals Limited2009-02-05Not applicableUs
Amlodipine BesylateTablet10 mg/1OralBiomes Pharmaceuticals LLC2011-04-15Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-03-11Not applicableUs
Amlodipine BesylateTablet5 mg/1OralWest Ward Pharmaceuticals Corp.2007-07-09Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralREMEDYREPACK INC.2015-02-18Not applicableUs
Amlodipine Besylate 10 mgTablet10 mg/1OralBi Coastal Pharma International Llc2016-10-05Not applicableUs
Amlodipine Besylate 2.5 mgTablet2.5 mg/1OralBi Coastal Pharma International Llc2016-10-05Not applicableUs
Amlodipine Besylate 5 mgTablet5 mg/1OralBi Coastal Pharma International Llc2016-10-05Not applicableUs
Apo-amlodipineTablet5.0 mgOralApotex Inc2009-07-09Not applicableCanada
Apo-amlodipineTablet10.0 mgOralApotex Inc2009-07-09Not applicableCanada
Apo-amlodipineTablet2.5 mgOralApotex IncNot applicableNot applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AforbesMerck
AgenZentiva
AkenKendrick Farmaceutica
AmcardApex Pharma Ltd
AmdepinCadila Pharmaceuticals
AmdipinLaboratorios Lafrancol
AmlocardAWD (Germany)
AmlodNot Available
AmlodineSumitomo Pharmaceuticals
AmlodipinNot Available
Amlodipin-Mepha 5/10Mepha Pharma AG
Amlodipine 5PT KALBE FARMA Tbk
AmlodisEczacibasi (Turkey)
AmlongMicro Labs
AmlopinLek
AmlopineBerlin
AmlostinDiscovery Pharmaceuticals
AmlosunSun Pharmaceutical
AmlovasMacleods Pharmaceuticals Ltd
AmlovascDr. Reddy's Laboratories
AmlozekAdamed
AmvazReddy (Malaysia)
AsomexEmcure Pharmaceuticals
Atecard-AMAlembic Ltd
CamlodinSquare
CorovalSandoz (Argentina)
DailyvascXeno Pharmaceuticals
IstinNot Available
LamaStadmed Private Limited
LodipTIME Pharmaceuticals
LodopinMerck Pakistan
LopinEdruc Ltd
NelodThe Kemiko Pharmaceuticals Ltd
NopidinAd-din Pharmaceuticals Ltd
NordipNot Available
PerivascNot Available
Pharex AmlodipinePHAREX HealthCorp
TenoxKrka
Brand mixtures
NameLabellerIngredients
AmlobenzRebel Distributors Corp
Amlodipine and Benazepril HydrochlorideTeva Pharmaceuticals USA Inc
Amlodipine and Olmesartan MedoxomilMacleods Pharmaceuticals Limited
Amlodipine and ValsartanSandoz Inc
Amlodipine Besylate and Atorvastatin CalciumMylan Pharmaceuticals Inc.
Amlodipine Besylate and Benazepril HClAmerican Health Packaging
Amlodipine Besylate and Benazepril HydrochlorideActavis Pharma, Inc.
Amlodipine Besylate and Olmesartan MedoxomilAjanta Pharma Limited
Amlodipine Besylate/atorvastatin CalciumMylan Pharmaceuticals Inc.
Amlodipine, Valsartan and HydrochlorothiazideTorrent Pharmaceuticals Limited
Amlodipine, Valsartan, and HydrochlorothiazideTeva Pharmaceuticals USA Inc
Amlodipine, Valsartan, HydrochlorothiazideSandoz Inc
AmturnideNovartis Pharmaceuticals Corporation
Apo-amlodipine-atorvastatinApotex Inc
AzorPhysicians Total Care, Inc.
CaduetPfizer Laboratories Div Pfizer Inc
DafiroNovartis Europharm Ltd.
ExforgeNovartis Pharmaceuticals Corporation
Exforge HctNovartis Pharmaceuticals Corporation
Gd-amlodipine/atorvastatinGenmed A Division Of Pfizer Canada Inc
HypertenipinePhysician Therapeutics Llc
ImpridaNovartis Europharm Ltd
Imprida HctNovartis Europharm Ltd.
LotrelNovartis Pharmaceuticals Corporation
Mylan-amlodipine/atorvastatinMylan Pharmaceuticals Ulc
Olmesartan Medoxomil / Amlodipine Besylate / HydrochlorothiazidePar Pharmaceutical, Inc.
Olmesartan Medoxomil, Amlodipine and HydrochlorothiazideSun Pharmaceutical Industries, Inc.
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 20/5/12.5 mgTorrent Pharmaceuticals Limited
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/10/12.5 mgTorrent Pharmaceuticals Limited
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/10/25 mgTorrent Pharmaceuticals Limited
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/5/12.5 mgTorrent Pharmaceuticals Limited
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/5/25 mgTorrent Pharmaceuticals Limited
Pendo-amlodipine-atorvastatinPendopharm Division Of De Pharmascience Inc
PMS-amlodipine-atorvastatinPharmascience Inc
PrestaliaSymplmed Pharmaceuticals, Llc
TekamloNovartis Pharmaceuticals Corporation
Telmisartan and AmlodipineMylan Pharmaceuticals Inc.
TribenzorDaiichi Sankyo, Inc.
TwynstaBoehringer Ingelheim Pharmaceuticals, Inc.
ViacoramServier Canada Inc
Salts
Name/CASStructureProperties
Amlodipine Besilate
ThumbNot applicableDBSALT001054
Amlodipine Besylate
ThumbNot applicableDBSALT001055
Amlodipine Maleate
ThumbNot applicableDBSALT001056
Categories
UNII1J444QC288
CAS number88150-42-9
WeightAverage: 408.876
Monoisotopic: 408.145199627
Chemical FormulaC20H25ClN2O5
InChI KeyHTIQEAQVCYTUBX-UHFFFAOYSA-N
InChI
InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3
IUPAC Name
3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
Pharmacology
IndicationFor the treatment of hypertension and chronic stable angina.
Structured Indications
PharmacodynamicsAmlodipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. It was widely accepted that DHP CCBs target L-type calcium channels, the major channel in muscle cells that mediate contraction; however, some studies have indicated that amlodipine also binds to and inhibits N-type calcium channels (see references in Targets section). Similar to other DHP CCBs, amlodipine binds directly to inactive L-type calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives amlodipine additional arterial selectivity. At therapeutic sub-toxic concentrations, amlodipine has little effect on cardiac myocytes and conduction cells.
Mechanism of actionAmlodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through L-type calcium channels. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of amlodipine result in an overall decrease in blood pressure. Amlodipine is a long-acting CCB that may be used to treat mild to moderate essential hypertension and exertion-related angina (chronic stable angina). Another possible mechanism is that amlodipine inhibits vascular smooth muscle carbonic anhydrase I activity causing cellular pH increases which may be involved in regulating intracelluar calcium influx through calcium channels.
TargetKindPharmacological actionActionsOrganismUniProt ID
Voltage-dependent L-type calcium channel subunit alpha-1CProteinyes
inhibitor
HumanQ13936 details
Voltage-dependent calcium channel subunit alpha-2/delta-1Proteinyes
inhibitor
HumanP54289 details
Voltage-dependent L-type calcium channel subunit beta-2Proteinyes
inhibitor
HumanQ08289 details
Voltage-dependent L-type calcium channel subunit alpha-1DProteinyes
inhibitor
HumanQ01668 details
Voltage-dependent L-type calcium channel subunit alpha-1SProteinyes
inhibitor
HumanQ13698 details
Voltage-dependent N-type calcium channel subunit alpha-1BProteinunknown
inhibitor
HumanQ00975 details
Voltage-dependent calcium channel subunit alpha-2/delta-3Proteinunknown
inhibitor
HumanQ8IZS8 details
Voltage-dependent L-type calcium channel subunit beta-1Proteinunknown
inhibitor
HumanQ6TME4 details
Carbonic anhydrase 1Proteinunknown
inhibitor
HumanP00915 details
Sphingomyelin phosphodiesteraseProteinunknownNot AvailableHumanP17405 details
Related Articles
AbsorptionAmlodipine is slowly and almost completely absorbed from the gastrointestinal tract. Peak plasma concentrations are reached 6-12 hour following oral administration. Its estimated bioavailability is 64-90%. Absorption is not affected by food.
Volume of distributionNot Available
Protein binding97.5%
Metabolism

Hepatic. Metabolized extensively (90%) to inactive metabolites via the cytochrome P450 3A4 isozyme.

Route of eliminationAmlodipine is extensively (about 90%) converted to inactive metabolites via hepatic metabolism with 10% of the parent compound and 60% of the metabolites excreted in the urine.
Half life30-50 hours
ClearanceNot Available
ToxicityGross overdosage could result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to an including shock with fatal outcome have been reported.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Amlodipine Action PathwayDrug actionSMP00376
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Natriuretic peptides A
Gene symbol: NPPA
UniProt: P01160
rs5065 Not AvailableAA alleleThose with the rs5065(AA) allele had more favorable cardiovascular disease outcomes if given amlodipine than if treated with chlorthalidone (diuretic)18212314
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Amlodipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Amlodipine.Vet Approved
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Amlodipine.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Acebutolol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Amlodipine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Amlodipine.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Amlodipine.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Amlodipine.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Amlodipine.Experimental
AlfuzosinAlfuzosin may increase the hypotensive activities of Amlodipine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Amlodipine is combined with Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Amlodipine.Approved, Investigational
AlprenololAmlodipine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Amlodipine.Approved, Investigational
AmifostineAmlodipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Amiloride.Approved
AmiodaroneThe metabolism of Amlodipine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Amlodipine.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Amlodipine.Approved
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Amlodipine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Amlodipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amlodipine is combined with Amyl Nitrite.Approved
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Amlodipine.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Amlodipine.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Amlodipine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Amlodipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Amlodipine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Amlodipine.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Amlodipine.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Amlodipine resulting in a loss in efficacy.Approved
AtazanavirThe metabolism of Amlodipine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Amlodipine.Approved
AtomoxetineThe metabolism of Amlodipine can be decreased when combined with Atomoxetine.Approved
AtosibanThe risk or severity of adverse effects can be increased when Amlodipine is combined with Atosiban.Approved
Atracurium besylateAmlodipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Amlodipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Azilsartan medoxomil.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Amlodipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Amlodipine.Experimental
BarbitalBarbital may increase the hypotensive activities of Amlodipine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Amlodipine.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Amlodipine.Approved
BepridilAmlodipine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Amlodipine.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Amlodipine.Approved
BethanidineBethanidine may increase the hypotensive activities of Amlodipine.Approved
BexaroteneThe serum concentration of Amlodipine can be decreased when it is combined with Bexarotene.Approved, Investigational
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Amlodipine.Approved
BimatoprostAmlodipine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Bisoprolol.Approved
BoceprevirThe metabolism of Amlodipine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Amlodipine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Amlodipine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Amlodipine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amlodipine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Amlodipine is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Amlodipine.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Amlodipine.Approved, Investigational
BucindololBucindolol may increase the hypotensive activities of Amlodipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Bupivacaine.Approved, Investigational
BupranololAmlodipine may increase the hypotensive activities of Bupranolol.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Amlodipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Amlodipine.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Amlodipine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Amlodipine.Approved
CalciumThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Amlodipine.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Amlodipine is combined with Candesartan.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Amlodipine.Withdrawn
CandoxatrilAmlodipine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Captopril.Approved
CarbamazepineThe metabolism of Amlodipine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Carbetocin.Approved
CarbomycinThe metabolism of Amlodipine can be decreased when combined with Carbomycin.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Amlodipine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Amlodipine.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Amlodipine is combined with Carvedilol.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Amlodipine.Approved
CeliprololAmlodipine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Amlodipine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Amlodipine.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Amlodipine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Chlorothiazide.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Amlodipine.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Amlodipine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Amlodipine.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Amlodipine.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Amlodipine can be increased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Amlodipine.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Amlodipine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Amlodipine.Approved
ClarithromycinThe metabolism of Amlodipine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Amlodipine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Amlodipine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Clofarabine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Amlodipine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Clonidine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Amlodipine.Approved, Nutraceutical
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Amlodipine.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Amlodipine.Approved
CobicistatThe metabolism of Amlodipine can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Amlodipine.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Amlodipine.Approved
ConivaptanThe serum concentration of Amlodipine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Amlodipine.Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Amlodipine.Investigational
CrizotinibThe metabolism of Amlodipine can be decreased when combined with Crizotinib.Approved
CryptenamineAmlodipine may increase the hypotensive activities of Cryptenamine.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Amlodipine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Amlodipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideAmlodipine may increase the hypotensive activities of Cyclothiazide.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amlodipine.Approved
DabrafenibThe serum concentration of Amlodipine can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Amlodipine.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Amlodipine.Investigational
DarunavirThe metabolism of Amlodipine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Amlodipine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Amlodipine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Amlodipine.Approved
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Amlodipine.Experimental
DeferasiroxThe serum concentration of Amlodipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Amlodipine can be decreased when combined with Delavirdine.Approved
DeserpidineAmlodipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Amlodipine is combined with Desflurane.Approved
DexamethasoneThe serum concentration of Amlodipine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Dexmedetomidine.Approved, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Amlodipine.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Amlodipine.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Diclofenamide.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Amlodipine.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Amlodipine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Amlodipine.Approved
DihydralazineAmlodipine may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe metabolism of Amlodipine can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Amlodipine.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Amlodipine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Amlodipine is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Amlodipine is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Amlodipine.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Amlodipine.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Amlodipine.Approved, Investigational, Vet Approved
DorzolamideAmlodipine may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Doxazosin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Amlodipine.Approved, Investigational
DoxycyclineThe metabolism of Amlodipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Amlodipine can be decreased when combined with Dronedarone.Approved
DuloxetineAmlodipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Amlodipine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Amlodipine.Approved
EfavirenzThe serum concentration of Amlodipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Amlodipine.Approved
EfonidipineAmlodipine may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Amlodipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Enalapril.Approved, Vet Approved
EnalaprilatAmlodipine may increase the hypotensive activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Amlodipine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Amlodipine.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Amlodipine is combined with Eplerenone.Approved
EpoprostenolAmlodipine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Amlodipine is combined with Eprosartan.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Amlodipine.Approved, Investigational
ErythromycinThe metabolism of Amlodipine can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Amlodipine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Amlodipine.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Amlodipine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Amlodipine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Amlodipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Amlodipine is combined with Etacrynic acid.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Amlodipine.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Amlodipine.Approved
EtravirineThe serum concentration of Amlodipine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Amlodipine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Amlodipine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Felodipine.Approved, Investigational
FenoldopamAmlodipine may increase the hypotensive activities of Fenoldopam.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amlodipine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Amlodipine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Amlodipine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Amlodipine is combined with Fimasartan.Approved
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Amlodipine.Approved
FluconazoleThe serum concentration of Amlodipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Amlodipine.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Amlodipine.Approved
FluvoxamineThe metabolism of Amlodipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Amlodipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Amlodipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Amlodipine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Amlodipine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Amlodipine can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Amlodipine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Amlodipine.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Amlodipine.Experimental
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Amlodipine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Amlodipine.Withdrawn
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Amlodipine.Approved, Vet Approved
GuanabenzAmlodipine may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Amlodipine.Approved
GuanethidineAmlodipine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Guanfacine.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Amlodipine.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Amlodipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Amlodipine is combined with Halothane.Approved, Vet Approved
HexamethoniumAmlodipine may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Amlodipine.Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Amlodipine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Amlodipine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Amlodipine.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Amlodipine.Approved, Vet Approved
HydroflumethiazideAmlodipine may increase the hypotensive activities of Hydroflumethiazide.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Amlodipine.Approved
IdelalisibThe serum concentration of Amlodipine can be increased when it is combined with Idelalisib.Approved
IloprostIloprost may increase the hypotensive activities of Amlodipine.Approved, Investigational
ImatinibThe metabolism of Amlodipine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Amlodipine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Amlodipine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Indapamide.Approved
IndenololAmlodipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Amlodipine can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Amlodipine.Approved, Investigational
IndoraminAmlodipine may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Amlodipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Amlodipine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Amlodipine is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Amlodipine.Approved, Investigational
IsavuconazoniumThe metabolism of Amlodipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Amlodipine.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Amlodipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Amlodipine is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Amlodipine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Amlodipine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Amlodipine.Approved
ItraconazoleThe metabolism of Amlodipine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Amlodipine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Amlodipine.Approved, Vet Approved
JosamycinThe metabolism of Amlodipine can be decreased when combined with Josamycin.Approved
KetanserinAmlodipine may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Amlodipine.Approved
KetoconazoleThe metabolism of Amlodipine can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Amlodipine can be decreased when combined with Kitasamycin.Experimental
LabetalolThe risk or severity of adverse effects can be increased when Amlodipine is combined with Labetalol.Approved
LacidipineAmlodipine may increase the hypotensive activities of Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Amlodipine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Amlodipine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Amlodipine.Approved, Investigational
LatanoprostAmlodipine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Amlodipine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Amlodipine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Amlodipine.Approved
LercanidipineAmlodipine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Amlodipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Levobupivacaine.Approved
LevodopaAmlodipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Amlodipine.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Amlodipine.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Amlodipine is combined with Levosimendan.Approved, Investigational
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Amlodipine.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Lisinopril.Approved, Investigational
LofexidineAmlodipine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Amlodipine.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Amlodipine.Approved
LopinavirThe metabolism of Amlodipine can be decreased when combined with Lopinavir.Approved
LosartanThe risk or severity of adverse effects can be increased when Amlodipine is combined with Losartan.Approved
LovastatinThe metabolism of Amlodipine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Amlodipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Amlodipine can be increased when combined with Lumacaftor.Approved
MacitentanAmlodipine may increase the hypotensive activities of Macitentan.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineAmlodipine may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Amlodipine is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Amlodipine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Mecamylamine.Approved
MelatoninMelatonin may decrease the antihypertensive activities of Amlodipine.Approved, Nutraceutical, Vet Approved
MethazolamideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Amlodipine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Amlodipine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amlodipine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Amlodipine is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Amlodipine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Amlodipine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Amlodipine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Amlodipine.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Amlodipine is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Amlodipine.Approved, Investigational
MetyrosineAmlodipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Amlodipine.Experimental
MibefradilAmlodipine may increase the hypotensive activities of Mibefradil.Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Amlodipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Amlodipine.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Amlodipine.Approved, Illicit
MifepristoneThe serum concentration of Amlodipine can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Amlodipine.Approved
MinaprineMinaprine may increase the hypotensive activities of Amlodipine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Amlodipine.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Amlodipine.Approved
MitotaneThe serum concentration of Amlodipine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Amlodipine.Approved, Investigational
MivacuriumAmlodipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Amlodipine.Approved
ModafinilThe serum concentration of Amlodipine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Amlodipine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Amlodipine.Vet Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Amlodipine.Approved, Investigational
MoxonidineAmlodipine may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Amlodipine.Approved, Investigational
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Amlodipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nadolol.Approved
NafcillinThe metabolism of Amlodipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Amlodipine.Approved
NaftopidilAmlodipine may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Amlodipine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Amlodipine.Approved, Vet Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Amlodipine.Approved
NebivololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Amlodipine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Amlodipine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Amlodipine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Amlodipine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Amlodipine.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Amlodipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nifedipine.Approved
NiguldipineAmlodipine may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Amlodipine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineAmlodipine may increase the hypotensive activities of Nilvadipine.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Amlodipine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Amlodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nisoldipine.Approved
NitrendipineAmlodipine may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nitroglycerin.Approved, Investigational
NitroprussideAmlodipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Amlodipine.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Amlodipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Amlodipine.Approved, Vet Approved
ObinutuzumabAmlodipine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Amlodipine.Withdrawn
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Amlodipine.Approved, Investigational
OlaparibThe metabolism of Amlodipine can be decreased when combined with Olaparib.Approved
OleandomycinThe metabolism of Amlodipine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Amlodipine.Approved, Investigational
OmapatrilatAmlodipine may increase the hypotensive activities of Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Amlodipine.Approved
OsimertinibThe serum concentration of Amlodipine can be increased when it is combined with Osimertinib.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Amlodipine.Approved
OxprenololAmlodipine may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Amlodipine.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Amlodipine.Investigational
PalbociclibThe serum concentration of Amlodipine can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Amlodipine.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Amlodipine.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Amlodipine.Approved
PenbutololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Amlodipine.Approved
PentobarbitalThe metabolism of Amlodipine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumAmlodipine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Amlodipine.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Amlodipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Amlodipine.Withdrawn
PhenobarbitalThe metabolism of Amlodipine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineAmlodipine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Amlodipine.Withdrawn
PhentolamineAmlodipine may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Amlodipine.Approved, Vet Approved
PimozideThe serum concentration of Pimozide can be increased when it is combined with Amlodipine.Approved
PinacidilAmlodipine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Amlodipine is combined with Pipamperone.Approved
PirlindolePirlindole may increase the hypotensive activities of Amlodipine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Amlodipine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Amlodipine.Withdrawn
PolythiazideAmlodipine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Amlodipine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Amlodipine.Approved
PosaconazoleThe metabolism of Amlodipine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Amlodipine is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Amlodipine.Approved
PrazosinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Amlodipine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Amlodipine.Approved, Vet Approved
PrimidoneThe metabolism of Amlodipine can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Amlodipine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Amlodipine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Propranolol.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Amlodipine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Amlodipine.Approved
QuinineQuinine may increase the hypotensive activities of Amlodipine.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Amlodipine.Experimental
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Amlodipine.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Amlodipine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Amlodipine.Approved, Investigational
RapacuroniumAmlodipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Amlodipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Amlodipine.Approved
RescinnamineAmlodipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Amlodipine.Approved
RifabutinThe metabolism of Amlodipine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Amlodipine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Amlodipine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Amlodipine.Approved, Investigational
RilmenidineAmlodipine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Amlodipine is combined with Riociguat.Approved
RisperidoneAmlodipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Amlodipine can be decreased when combined with Ritonavir.Approved, Investigational
RituximabAmlodipine may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Amlodipine.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Amlodipine.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Amlodipine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Amlodipine.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Amlodipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Amlodipine.Approved, Vet Approved
SaprisartanAmlodipine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Amlodipine can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Amlodipine.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Amlodipine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Amlodipine.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Amlodipine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Amlodipine is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Amlodipine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Amlodipine.Approved
SiltuximabThe serum concentration of Amlodipine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Amlodipine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Amlodipine.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Amlodipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Amlodipine.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Amlodipine.Approved, Investigational
SitaxentanAmlodipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Amlodipine is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Amlodipine.Approved
SolithromycinThe metabolism of Amlodipine can be decreased when combined with Solithromycin.Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Amlodipine.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Amlodipine is combined with Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Amlodipine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Amlodipine.Experimental
SpiraprilAmlodipine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Amlodipine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Amlodipine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Amlodipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Amlodipine is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Sufentanil.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Amlodipine.Approved
SulfisoxazoleThe metabolism of Amlodipine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Amlodipine.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Amlodipine.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Amlodipine.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Amlodipine.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Amlodipine.Experimental
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Amlodipine.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Amlodipine.Approved
TelaprevirThe metabolism of Amlodipine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Amlodipine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Amlodipine is combined with Telmisartan.Approved, Investigational
TemocaprilAmlodipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Amlodipine.Approved
TerazosinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Terazosin.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Amlodipine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Amlodipine.Approved
TerlipressinAmlodipine may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Amlodipine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Amlodipine.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Amlodipine.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Amlodipine.Approved
TiboloneAmlodipine may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Amlodipine.Approved
TiclopidineThe metabolism of Amlodipine can be decreased when combined with Ticlopidine.Approved
TicrynafenAmlodipine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Amlodipine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Amlodipine.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Amlodipine.Approved
TocilizumabThe serum concentration of Amlodipine can be decreased when it is combined with Tocilizumab.Approved
TolazolineAmlodipine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Amlodipine is combined with Tolcapone.Approved, Withdrawn
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Amlodipine.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypotensive activities of Amlodipine.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Amlodipine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Amlodipine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Amlodipine.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Amlodipine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Amlodipine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Amlodipine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Amlodipine.Approved
TravoprostTravoprost may increase the hypotensive activities of Amlodipine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Amlodipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Amlodipine is combined with Triamterene.Approved
TrichlormethiazideAmlodipine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinAmlodipine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanAmlodipine may increase the hypotensive activities of Trimethaphan.Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Amlodipine.Approved, Investigational
TroleandomycinThe metabolism of Amlodipine can be decreased when combined with Troleandomycin.Approved
TylosinThe metabolism of Amlodipine can be decreased when combined with Tylosin.Vet Approved
UdenafilUdenafil may increase the antihypertensive activities of Amlodipine.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Amlodipine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Amlodipine.Approved
UnoprostoneAmlodipine may increase the hypotensive activities of Unoprostone.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Amlodipine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Amlodipine.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Amlodipine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Amlodipine.Approved
VenlafaxineThe metabolism of Amlodipine can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Verapamil.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Amlodipine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Amlodipine.Approved, Investigational
VinpocetineAmlodipine may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Amlodipine.Approved
VoriconazoleThe metabolism of Amlodipine can be decreased when combined with Voriconazole.Approved, Investigational
XylometazolineAmlodipine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Amlodipine.Approved, Vet Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Amlodipine.Approved
ZiprasidoneThe metabolism of Amlodipine can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Avoid natural licorice.
  • Grapefruit down regulates post-translational expression of CYP3A4, the major metabolizing enzyme of amlodipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of amlodipine and may cause toxicity. Avoid grapefruit products while on this medication.
  • Take without regard to meals.
References
Synthesis Reference

DrugSyn.org

US4572909
General References
  1. Nayler WG, Gu XH: The unique binding properties of amlodipine: a long-acting calcium antagonist. J Hum Hypertens. 1991 Aug;5 Suppl 1:55-9. [PubMed:1834847 ]
  2. van Zwieten PA: Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties. Clin Cardiol. 1994 Sep;17(9 Suppl 3):III3-6. [PubMed:9156957 ]
External Links
ATC CodesC09DB01C09DX03C09DB04C09DB05C09DX01C08GA02C10BX11C09DB06C09DB07C09DB02C10BX03C09BB03C09BB07C08CA01C09XA54C09XA53C09BB04C10BX09C10BX07C09BX01
AHFS Codes
  • 24:28.08
PDB Entries
FDA labelDownload (91.4 KB)
MSDSDownload (74.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9479
Blood Brain Barrier-0.7744
Caco-2 permeable-0.5468
P-glycoprotein substrateSubstrate0.9102
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IINon-inhibitor0.8473
Renal organic cation transporterNon-inhibitor0.803
CYP450 2C9 substrateNon-substrate0.8627
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6967
CYP450 1A2 substrateInhibitor0.538
CYP450 2C9 inhibitorInhibitor0.514
CYP450 2D6 inhibitorNon-inhibitor0.7626
CYP450 2C19 inhibitorInhibitor0.5871
CYP450 3A4 inhibitorInhibitor0.8608
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6642
Ames testNon AMES toxic0.7605
CarcinogenicityNon-carcinogens0.8568
BiodegradationNot ready biodegradable0.9791
Rat acute toxicity2.5396 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8302
hERG inhibition (predictor II)Inhibitor0.8411
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Synthon pharmaceuticals inc
  • Actavis totowa llc
  • Alkem laboratories ltd
  • Amneal pharmaceuticals ny llc
  • Apotex inc
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Dr reddys laboratories ltd
  • Gedeon richter usa inc
  • Genpharm inc
  • Glenmark generics ltd
  • Invagen pharmaceuticals inc
  • Lek pharmaceuticals dd
  • Lupin ltd
  • Matrix laboratories ltd
  • Mutual pharmacal co
  • Mylan laboratories inc
  • Orchid healthcare
  • Ranbaxy laboratories ltd
  • Roxane laboratories inc
  • Teva pharmaceuticals usa inc
  • Torrent pharmaceuticals ltd
  • Upsher smith laboratories inc
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • Wockhardt ltd
  • World gen llc
  • Zydus pharmaceuticals usa inc
  • Pfizer inc
  • Dr reddys laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral10.00 mg
TabletOral5.00 mg
Tablet, film coatedOral
TabletOral2.5 mg
Kit
CapsuleOral
TabletOral10.0 mg
TabletOral5.0 mg
TabletOral10 mg/1
TabletOral2.5 mg/1
TabletOral5 mg/1
TabletOral10 mg
TabletOral5 mg
TabletOral
Tablet, multilayerOral
Prices
Unit descriptionCostUnit
Amlodipine besylate powder9.99USD g
Lotrel 10-40 mg capsule5.21USD capsule
Lotrel 10-20 mg capsule4.8USD capsule
Lotrel 5-40 mg capsule4.37USD capsule
Lotrel 5-20 mg capsule4.13USD capsule
Lotrel 5-10 mg capsule3.91USD capsule
Lotrel 2.5-10 mg capsule3.83USD capsule
Norvasc 10 mg tablet3.16USD tablet
Amlodipine besylate 10 mg tablet2.42USD tablet
Norvasc 2.5 mg tablet2.36USD tablet
Norvasc 5 mg tablet2.36USD tablet
Norvasc 10 mg Tablet2.14USD tablet
Amlodipine besylate 2.5 mg tablet1.76USD tablet
Amlodipine besylate 5 mg tablet1.76USD tablet
Norvasc 5 mg Tablet1.44USD tablet
Amlodipine 10 mg Tablet1.03USD tablet
Apo-Amlodipine 10 mg Tablet1.03USD tablet
Co Amlodipine 10 mg Tablet1.03USD tablet
Gd-Amlodipine 10 mg Tablet1.03USD tablet
Jamp-Amlodipine 10 mg Tablet1.03USD tablet
Mylan-Amlodipine 10 mg Tablet1.03USD tablet
Novo-Amlodipine 10 mg Tablet1.03USD tablet
Phl-Amlodipine 10 mg Tablet1.03USD tablet
Pms-Amlodipine 10 mg Tablet1.03USD tablet
Ran-Amlodipine 10 mg Tablet1.03USD tablet
Ratio-Amlodipine 10 mg Tablet1.03USD tablet
Sandoz Amlodipine 10 mg Tablet1.03USD tablet
Amlodipine 5 mg Tablet0.7USD tablet
Apo-Amlodipine 5 mg Tablet0.7USD tablet
Co Amlodipine 5 mg Tablet0.7USD tablet
Gd-Amlodipine 5 mg Tablet0.7USD tablet
Jamp-Amlodipine 5 mg Tablet0.7USD tablet
Mylan-Amlodipine 5 mg Tablet0.7USD tablet
Novo-Amlodipine 5 mg Tablet0.7USD tablet
Phl-Amlodipine 5 mg Tablet0.7USD tablet
Pms-Amlodipine 5 mg Tablet0.7USD tablet
Ran-Amlodipine 5 mg Tablet0.7USD tablet
Ratio-Amlodipine 5 mg Tablet0.7USD tablet
Sandoz Amlodipine 5 mg Tablet0.7USD tablet
Phl-Amlodipine 2.5 mg Tablet0.35USD tablet
Pms-Amlodipine 2.5 mg Tablet0.35USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2170278 No1999-08-032014-08-10Canada
US5559111 No1998-07-212018-07-21Us
US5616599 Yes1996-10-252016-10-25Us
US5969156 Yes1997-01-082017-01-08Us
US6162802 No1997-12-192017-12-19Us
US6294197 Yes1997-12-182017-12-18Us
US6395728 No1999-07-082019-07-08Us
US6455574 No1998-08-112018-08-11Us
US6696481 No2003-04-152023-04-15Us
US6828339 No2002-11-202022-11-20Us
US7846961 No2009-10-052029-10-05Us
US8101599 No2003-05-162023-05-16Us
US8183295 No2003-05-162023-05-16Us
US8475839 Yes2003-11-162023-11-16Us
US8613949 No2009-12-212029-12-21Us
US8618174 No2001-11-152021-11-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point178-179 °CNot Available
water solubility75.3 mg/LNot Available
logP3.00AUSTIN,RP ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0074 mg/mLALOGPS
logP2.22ALOGPS
logP1.64ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)9.45ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.88 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity108.64 m3·mol-1ChemAxon
Polarizability42.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassHydropyridines
Direct ParentDihydropyridinecarboxylic acids and derivatives
Alternative Parents
Substituents
  • Dihydropyridinecarboxylic acid derivative
  • Halobenzene
  • Chlorobenzene
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Vinylogous amide
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Methyl ester
  • Carboxylic acid ester
  • Azacycle
  • Ether
  • Enamine
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).
Gene Name:
CACNA2D1
Uniprot ID:
P54289
Molecular Weight:
124566.93 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1B gives rise to N-type calcium currents. N-type calcium channels belong to the 'high-...
Gene Name:
CACNA1B
Uniprot ID:
Q00975
Molecular Weight:
262493.84 Da
References
  1. Furukawa T, Nukada T, Suzuki K, Fujita Y, Mori Y, Nishimura M, Yamanaka M: Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine. Br J Pharmacol. 1997 Jul;121(6):1136-40. [PubMed:9249249 ]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060 ]
  3. Miyashita Y, Furukawa T, Kamegaya E, Yoshii M, Nukada T: A region of N-type Ca(2+) channel critical for blockade by the dihydropyridine amlodipine. Eur J Pharmacol. 2010 Apr 25;632(1-3):14-22. doi: 10.1016/j.ejphar.2010.01.006. Epub 2010 Jan 22. [PubMed:20097194 ]
  4. Murakami M, Nakagawasai O, Fujii S, Kameyama K, Murakami S, Hozumi S, Esashi A, Taniguchi R, Yanagisawa T, Tan-no K, Tadano T, Kitamura K, Kisara K: Antinociceptive action of amlodipine blocking N-type Ca2+ channels at the primary afferent neurons in mice. Eur J Pharmacol. 2001 May 11;419(2-3):175-81. [PubMed:11426839 ]
  5. Ogihara T, Kano T, Kakinuma C: Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling. Arzneimittelforschung. 2009;59(6):283-8. doi: 10.1055/s-0031-1296398. [PubMed:19634509 ]
  6. Qu YL, Sugiyama K, Ohnuki T, Hattori K, Watanabe K, Nagatomo T: Comparison of binding affinities of omega-conotoxin and amlodipine to N-type Ca2+ channels in rat brain. Zhongguo Yao Li Xue Bao. 1998 Mar;19(2):97-100. [PubMed:10374627 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated ion channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) but not T-type (CACNA1G) (By similarity).
Gene Name:
CACNA2D3
Uniprot ID:
Q8IZS8
Molecular Weight:
123010.22 Da
References
  1. Furukawa T, Nukada T, Suzuki K, Fujita Y, Mori Y, Nishimura M, Yamanaka M: Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine. Br J Pharmacol. 1997 Jul;121(6):1136-40. [PubMed:9249249 ]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060 ]
  3. Miyashita Y, Furukawa T, Kamegaya E, Yoshii M, Nukada T: A region of N-type Ca(2+) channel critical for blockade by the dihydropyridine amlodipine. Eur J Pharmacol. 2010 Apr 25;632(1-3):14-22. doi: 10.1016/j.ejphar.2010.01.006. Epub 2010 Jan 22. [PubMed:20097194 ]
  4. Murakami M, Nakagawasai O, Fujii S, Kameyama K, Murakami S, Hozumi S, Esashi A, Taniguchi R, Yanagisawa T, Tan-no K, Tadano T, Kitamura K, Kisara K: Antinociceptive action of amlodipine blocking N-type Ca2+ channels at the primary afferent neurons in mice. Eur J Pharmacol. 2001 May 11;419(2-3):175-81. [PubMed:11426839 ]
  5. Ogihara T, Kano T, Kakinuma C: Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling. Arzneimittelforschung. 2009;59(6):283-8. doi: 10.1055/s-0031-1296398. [PubMed:19634509 ]
  6. Qu YL, Sugiyama K, Ohnuki T, Hattori K, Watanabe K, Nagatomo T: Comparison of binding affinities of omega-conotoxin and amlodipine to N-type Ca2+ channels in rat brain. Zhongguo Yao Li Xue Bao. 1998 Mar;19(2):97-100. [PubMed:10374627 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
High voltage-gated calcium channel activity
Specific Function:
Not Available
Gene Name:
CACNB1
Uniprot ID:
Q6TME4
Molecular Weight:
23836.425 Da
References
  1. Furukawa T, Nukada T, Suzuki K, Fujita Y, Mori Y, Nishimura M, Yamanaka M: Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine. Br J Pharmacol. 1997 Jul;121(6):1136-40. [PubMed:9249249 ]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060 ]
  3. Miyashita Y, Furukawa T, Kamegaya E, Yoshii M, Nukada T: A region of N-type Ca(2+) channel critical for blockade by the dihydropyridine amlodipine. Eur J Pharmacol. 2010 Apr 25;632(1-3):14-22. doi: 10.1016/j.ejphar.2010.01.006. Epub 2010 Jan 22. [PubMed:20097194 ]
  4. Murakami M, Nakagawasai O, Fujii S, Kameyama K, Murakami S, Hozumi S, Esashi A, Taniguchi R, Yanagisawa T, Tan-no K, Tadano T, Kitamura K, Kisara K: Antinociceptive action of amlodipine blocking N-type Ca2+ channels at the primary afferent neurons in mice. Eur J Pharmacol. 2001 May 11;419(2-3):175-81. [PubMed:11426839 ]
  5. Ogihara T, Kano T, Kakinuma C: Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling. Arzneimittelforschung. 2009;59(6):283-8. doi: 10.1055/s-0031-1296398. [PubMed:19634509 ]
  6. Qu YL, Sugiyama K, Ohnuki T, Hattori K, Watanabe K, Nagatomo T: Comparison of binding affinities of omega-conotoxin and amlodipine to N-type Ca2+ channels in rat brain. Zhongguo Yao Li Xue Bao. 1998 Mar;19(2):97-100. [PubMed:10374627 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:
CA1
Uniprot ID:
P00915
Molecular Weight:
28870.0 Da
References
  1. Puscas I, Gilau L, Coltau M, Pasca R, Domuta G, Baican M, Hecht A: Hypotensive effect of calcium channel blockers is parallel with carbonic anhydrase I inhibition. Clin Pharmacol Ther. 2000 Oct;68(4):443-9. [PubMed:11061585 ]
  2. Puscas L, Gilau L, Coltau M, Pasca R, Domuta G, Baican M, Hecht A: Calcium channel blockers reduce blood pressure in part by inhibiting vascular smooth muscle carbonic anhydrase I. Cardiovasc Drugs Ther. 2000 Oct;14(5):523-8. [PubMed:11101200 ]
  3. Puscas I, Coltau M, Baican M, Pasca R, Domuta G, Hecht A: Vasoconstrictive drugs increase carbonic anhydrase I in vascular smooth muscle while vasodilating drugs reduce the activity of this isozyme by a direct mechanism of action. Drugs Exp Clin Res. 2001;27(2):53-60. [PubMed:11392054 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sphingomyelin phosphodiesterase activity
Specific Function:
Converts sphingomyelin to ceramide. Also has phospholipase C activities toward 1,2-diacylglycerolphosphocholine and 1,2-diacylglycerolphosphoglycerol. Isoform 2 and isoform 3 have lost catalytic activity.
Gene Name:
SMPD1
Uniprot ID:
P17405
Molecular Weight:
69751.3 Da
References
  1. Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, Muhle C, Terfloth L, Groemer TW, Spitzer GM, Liedl KR, Gulbins E, Tripal P: Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One. 2011;6(8):e23852. doi: 10.1371/journal.pone.0023852. Epub 2011 Aug 31. [PubMed:21909365 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T: Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52. [PubMed:10805063 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T: Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52. [PubMed:10805063 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T: Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52. [PubMed:10805063 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T: Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52. [PubMed:10805063 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res. 2000 Oct;17(10):1189-97. [PubMed:11145223 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 03:58